BWX Technologies Inc is a specialty manufacturer and service provider of nuclear components, operating in two segments: Government Operations and Commercial Operations... Show more
BWX Technologies, a key supplier of nuclear components to the U.S. government and commercial markets, released first quarter 2026 results for the three months ended March 31, 2026. This report is critical amid rising demand for nuclear propulsion in naval programs and commercial nuclear revival. The company has consistently beaten earnings estimates over the past four quarters, reflecting strong execution on a growing backlog. With geopolitical tensions boosting defense spending and clean energy initiatives favoring nuclear power, investors watch BWXT closely for signals on government contracts, commercial nuclear growth, and margins in a high-demand environment. Strong results underscore BWXT's strategic position in secure nuclear manufacturing.
BWX Technologies delivered robust Q1 2026 results, exceeding analyst expectations across key metrics. Revenue reached $860.2 million, a 26% increase from $682.3 million in Q1 2025 and above the consensus of about $837 million, fueled by 11% organic growth. Government Operations revenue rose 4% to $577.9 million, supported by special materials and naval propulsion. Commercial Operations exploded 121% to $283.6 million (39% organic), driven by nuclear components, field services, fuel, and medical radioisotopes.
GAAP net income climbed 21% to $91.2 million, with diluted EPS at $0.99 (up from $0.82). Non-GAAP diluted EPS hit $1.12, up 22% year-over-year and beating forecasts of $0.92 by 21.7%, aided by operational leverage and lower interest expense. Adjusted EBITDA grew 14% to $148.0 million (margin 17.2%), reflecting higher throughput and efficiency. Operating cash flow surged 83% to $92.6 million, and free cash flow jumped 190% to $50.1 million. Total backlog stood at $8.65 billion, providing strong visibility.
Guidance was raised for full-year 2026 (calendar year ending December 31): revenue >$3.75 billion (high-teens growth), adjusted EBITDA $650-$665 million (low-to-mid teens growth), non-GAAP EPS $4.60-$4.75, and free cash flow $315-$330 million, excluding the pending Precision Components acquisition.
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock discovery process.
Despite beating earnings and revenue estimates and raising guidance, BWXT shares declined post-release. The stock dipped slightly in after-hours on May 4 before plunging 4.86% on May 5, closing at $206.15 on elevated volume of over 1.7 million shares (high $227.12, low $203.05). The "sell-the-news" dynamic appears at play, as the stock had rallied into earnings on anticipation of strong nuclear demand. Investors may view the guidance raise as modest relative to consensus, focusing on execution risks in commercial scaling and government contract pacing amid a rich valuation.
BWX Technologies enters the year with momentum, backed by a record $8.65 billion backlog—$6.93 billion in Government Operations and $1.72 billion in Commercial. The raised 2026 guidance signals confidence in high-teens revenue growth, with Government expecting low-teens expansion (double-digit in special materials, low-single in naval propulsion) and Commercial around 30% (low-teens organic plus acquisitions like Kinectrics).
Investors should track segment margins: Government >19% adjusted EBITDA margin, Commercial ~14%. Free cash flow generation remains key, with capex at ~6% of sales and tax rate below 21.5%. The announced acquisition of Precision Components Group will bolster U.S. commercial nuclear manufacturing capacity, but integration and contribution (excluded from guidance) warrant monitoring.
Broader catalysts include U.S. naval nuclear propulsion awards, commercial nuclear fuel demand, and medical radioisotope ramp-up. Risks involve supply chain pressures, labor shortages in nuclear skilled trades, and government funding delays. Upcoming Q2 results on August 3 will provide updates on backlog conversion and organic progress.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a provider of components and services to nuclear power industry
Industry AerospaceDefense